Flunitrazepam

Flunitrazepam, marketed under the brand name Rohypnol by Roche, is a potent intermediate-to-long-acting nitrobenzodiazepine approximately 10 times more potent than diazepam. It produces pronounced sedation, anxiolysis, anterograde amnesia, and muscle relaxation, and has legitimate pharmaceutical applications in anesthesia and the short-term treatment of severe insomnia in countries where it is licensed. In the United States, flunitrazepam has never been approved for medical use and is classified as a Schedule IV controlled substance (despite being unapproved), reflecting its high abuse potential and association with drug-facilitated sexual assault — a designation that makes its importation a federal offense.

Flunitrazepam became notorious in the United States and elsewhere from the early 1990s onward as a "date rape drug," primarily because its combination of profound sedation, anterograde amnesia, and (in older formulations) water solubility made it suitable for covert administration in beverages. Roche responded to this concern in the mid-1990s by reformulating the tablet to contain a blue dye that discolors clear liquids and makes the tablet harder to dissolve invisibly. However, generic and counterfeit versions may not contain these safety features.

The term "roofies" has become a generic colloquialism for drug-facilitated sexual assault drugs generally, though the actual prevalence of flunitrazepam specifically relative to other drugs (including alcohol) in such assaults has been contested by toxicological evidence. From a pharmacological harm reduction perspective, flunitrazepam's profile — high potency, pronounced amnesia, respiratory depression potential, and severe dependence/withdrawal risk — is shared by several other benzodiazepines; its cultural notoriety does not make it uniquely dangerous among the class, though its specific association with assault warrants clear harm reduction messaging.